BioCryst Pharmaceuticals | BCRX - 销售成本



金融业
股票价格
USD
资产
USD 465.05M
现金及等价物
USD 171.59M
销售成本
USD 9.52M
流动资产
USD 373.63M
流动负债
USD 195.39M
债务
USD 828.6M
股息收益率
0
EBIT
USD 260.39M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 1.17
股本和储备
USD -553.84M
销售毛利
USD 153.05M
债务利息支出
USD 14.14M
利息收入
USD -0.13
贷款资金
USD 395.2M
市值
USD 1.96B
净收入
USD 245.85M
营业费用
USD -553.84M
营业利润
USD 260.39M
普通股股本
USD 213.06M
PE价格收益
6.06
税前利润
USD 248.02M
销售收入
USD 406.56M
销售和管理费用
USD 95.78M
股票
USD 5.99M
贸易债权人
USD 10.96M
应收帐款人
USD 106.82M


销售成本 更改 日
Alnylam Pharmaceuticals USD 211.12M 56.6M 2026-03
BioCryst Pharmaceuticals USD 9.52M 7.34M 2025-12
Chugai Pharma JPY 92.79B 5.23B 2026-03
Daiichi Sankyo JPY 118.28B 37.7B 2025-12
Gilead Sciences USD 1.44B 174M 2026-03
GlaxoSmithKline GBP 1.88B 736M 2026-03
Glaxosmithkline GBP 1.88B 1.6B 2026-03
Incyte USD 104.5M 16.68M 2026-03
Ionis Pharmaceuticals USD 3M 5M 2026-03
Karyopharm Therapeutics USD 1.48M 35.95M 2025-12
Neurocrine Biosciences USD 13.8M 3.8M 2026-03
Novavax USD 22.1M 608K 2025-12
PTC Therapeutics USD 39.61M 23.31M 2026-03
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Roche Holding CHF 8.48B 4.61B 2025-12
Sarepta Therapeutics USD 109.46M 289.93M 2026-03
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Vertex Pharmaceuticals USD 392.8M 73.2M 2026-03